Respiratory Syncytial Virus (RSV)

Beyond Ebola, keeping patients and health workers safe

Dr Doussou Touré arrives for work at Coléah Medical Centre. She washes her hands from a bucket set up in front of the building, proceeds to a screening area where her temperature is checked and recorded and only then enters the bustling facility that she supervises.
“Ebola is under control now, but we try to keep up the infection prevention and control systems that were put in place during the outbreak,” Dr Touré says, pointing to several sturdy, brightly-coloured bins, each one designated for the disposal of varying waste matter.

Bavarian Nordic to start PhI trial of RSV jab

Things are heating up in the race for a respiratory syncytial virus (RSV) vaccine. Novavax reported Phase II results for its investigational vaccine just a week ago, and now, Danish biotech Bavarian Nordic is starting a Phase I trial of its candidate.

Novavax: Study indicates vaccine effective vs. RSV

Trenton, N.J. — Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable Americans — babies and senior citizens.
If further testing by vaccine developer Novavax Inc. goes well, in a few years the biotech company’s genetically engineered shot could become the first vaccine approved against respiratory syncytial virus, or RSV.

New report sheds light on the respiratory syncytial virus (rsv) infections research report - pipeline review, H1 2015

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.


Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University.
The findings, published on July 14 in the International Journal of Nanomedicine, suggest this vaccine induces long-term protection against RSV and could serve as a novel treatment option for this disease. There is currently no licensed RSV vaccine.

AstraZeneca's MedImmune gets RSV candidate fast-tracked

Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus (RSV) to market--and one just picked up a regulatory boost.
MedImmune, AstraZeneca's ($AZN) biologics research and development arm, announced on Thursday that the FDA is fast-tracking its RSV vaccine, MEDI8897. It joins Novavax ($NVAX), which received FDA fast-track designation for its candidate in November.

Novavax tests RSV vaccine for children

Novavax, Inc., announced on Monday that it has begun enrolling pediatric participants in a Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine).
The study will be conducted on 150 healthy Canadian children ranging aged two to six and is the first study of this potential vaccine to be done using children.

NIH scientists develop candidate vaccine against respiratory syncytial virus

An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.


Nanoparticle vaccine offers better protection: Particles that deliver vaccines directly to mucosal surfaces could defend against many infectious diseases

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.